Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Human Immunodeficiency Virus-Type 1”

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00513526
What this trial is testing

Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection

Who this might be right for
InfectionPrecancerous Condition
AIDS Malignancy Consortium 112
Not applicableLooking for participantsNCT04174755
What this trial is testing

Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV

Who this might be right for
ObesityHIV-1-infection
University College Dublin 80
Testing effectiveness (Phase 2)Study completedNCT00004584
What this trial is testing

Safety and Effectiveness of a New Protease Inhibitor, BMS-232632, in HIV-Positive Patients Who Have Received Previous Treatment

Who this might be right for
HIV Infections
Bristol-Myers Squibb
Early research (Phase 1)Study completedNCT00000884
What this trial is testing

Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 84
Post-approval studies (Phase 4)Study completedNCT00224445
What this trial is testing

Boosted Atazanavir and Truvada Given Once-Daily - BATON Study

Who this might be right for
HIV Infections
Gilead Sciences 100
Large-scale testing (Phase 3)Study completedNCT00573001
What this trial is testing

Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA)

Who this might be right for
HIV Infections
French National Agency for Research on AIDS and Viral Hepatitis 120
Large-scale testing (Phase 3)Study completedNCT00352053
What this trial is testing

Safety and Efficacy of Tenofovir DF in HIV-1 Infected Adolescents Failing Their Current Antiretroviral Therapy

Who this might be right for
HIV Infections
Gilead Sciences 87
Post-approval studies (Phase 4)UnknownNCT03017872
What this trial is testing

Dolutegravir and Darunavir Evaluation in Adults Failing Therapy

Who this might be right for
HIV Infections
Kirby Institute 831
Large-scale testing (Phase 3)Study completedNCT02157311
What this trial is testing

4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV Patients

Who this might be right for
HIV-1 Infection
ANRS, Emerging Infectious Diseases 100
Not applicableUnknownNCT04878601
What this trial is testing

Innovative Strategies to Increase ART Initiation and Viral Suppression Among HIV-positive Men in Malawi

Who this might be right for
Hiv
University of California, Los Angeles 470
Not applicableStudy completedNCT00002312
What this trial is testing

The Safety and Effectiveness of U-90152 in HIV-1 Infected Patients Who Take Zidovudine

Who this might be right for
HIV Infections
Pharmacia and Upjohn
Post-approval studies (Phase 4)Study completedNCT05243602
What this trial is testing

BFTAF Elderly Switch Study

Who this might be right for
HIV-1-infection
University of Nairobi 520
Not applicableStudy completedNCT01823614
What this trial is testing

Co-receptor Tropism Determination of HIV-1 Subtype A Spread in the Russian Federation Using V3-based Genotyping Tools

Who this might be right for
HIV Infection
Dmitry Kireev 943
Post-approval studies (Phase 4)Study completedNCT01641367
What this trial is testing

A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure

Who this might be right for
HIV-1 Infection
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections 545
Large-scale testing (Phase 3)Study completedNCT02105987
What this trial is testing

A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen

Who this might be right for
Infection, Human Immunodeficiency Virus
ViiV Healthcare 555
Early research (Phase 1)Study completedNCT03783130
What this trial is testing

Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults

Who this might be right for
Human Immunodeficiency Virus PreventionHuman Immunodeficiency Virus (HIV)
National Institute of Allergy and Infectious Diseases (NIAID) 16
Testing effectiveness (Phase 2)Study completedNCT00880698
What this trial is testing

Safety and Immune Response of a Rotavirus Vaccine in HIV-infected and Uninfected Children Born to HIV-infected Mothers

Who this might be right for
HIV InfectionRotavirus Infection
National Institute of Allergy and Infectious Diseases (NIAID) 202
Early research (Phase 1)Study completedNCT00026624
What this trial is testing

Safety/Immunogenicity of Immunizations of ALVAC-DC-SC vs ALVAC-SC

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID)
Testing effectiveness (Phase 2)Study completedNCT03560258
What this trial is testing

HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) Vaccine Study

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 45
Early research (Phase 1)Study completedNCT00000738
What this trial is testing

Randomized, Double-Blind, Placebo-Controlled Trial of Nimodipine for the Neurological Manifestations of HIV-1

Who this might be right for
AIDS Dementia ComplexHIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 36
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation